TIDMAGY
RNS Number : 0772M
Allergy Therapeutics PLC
10 October 2016
10 October 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Allergy Therapeutics presents enhanced efficacy data in a
malaria vaccine model
with its novel adjuvant system
Data to be presented today at the World Vaccine Congress
demonstrates significant improvements in effective infectious
disease applications using Bencard Adjuvant Systems technology
Allergy Therapeutics (AIM:AGY), the fully integrated
pharmaceutical company specialising in allergy vaccines, together
with its wholly-owned division, Bencard Adjuvant Systems (BAS),
which specialises in developing and optimising adjuvants for
prophylactic vaccination and allergen immunotherapy, announces new
data using a novel adjuvant system that shows enhancement of
efficacy in a malaria vaccine model. These results will be
presented today at the World Vaccine Congress in Barcelona, Spain
at 16:00 CET.
In an oral session entitled: "Platform technologies to emerging
pathogens", Allergy Therapeutics' principal scientist, Dr Matthew
Heath, PhD, in conjunction with the Jenner Institute, University of
Oxford, will present new information on adjuvant activity and
enhanced efficacy in a candidate vaccine formulation against
Plasmodium vivax (malaria). Microcrystalline tyrosine (MCT), the
aluminium-free depot adjuvant used in Allergy Therapeutics'
successfully marketed and rapidly growing Pollinex Quattro(R)
immunotherapy product, was shown to elicit high, sustained antibody
titres in a preclinical model and demonstrated increased protective
efficacy compared to existing adjuvants.
Furthermore, Dr Heath will discuss how MCT has synergistic
effects when coupled with Virus Like Particles (VLP) to create a
combined and unique Adjuvant System, AdSys-VcT. The data indicated
a significant increase in specific antibodies and other immune
parameters indicative of protective efficacy compared to aluminium
salts. The potential for this novel adjuvant system in infectious
disease applications was concluded to be highly significant.
Allergy Therapeutics has been pioneering the development of
novel adjuvant systems with the combination of MCT and
monophosphoryl lipid A (MPL) in allergy immunotherapy, allowing for
the successful introduction of the concept of ultra-short course
immunotherapy in the allergy vaccines market.
BAS, the fully owned Allergy Therapeutics division specialising
in adjuvant systems, has signed a Memorandum of Understanding with
Saiba GmbH, the Swiss-based vaccines company, to develop new
applications of its novel adjuvant system, AdSys-VcT, for use in
prophylactic vaccination and food allergy immunotherapy. BAS has a
portfolio of adjuvants with certain exclusive rights.
Dr Murray Skinner, Chief Scientific Officer of Allergy
Therapeutics, said: "Our positive data on adjuvant development is
great news in an environment where organisations such as the US
National Institutes of Health describe a significant unmet need for
adjuvants suitable for use in combination with the growing number
of emerging and evolving infectious disease targets(1) . These data
support our belief that Bencard Adjuvant Systems has a potentially
wide range of applications and we look forward to further results
and collaborations, such as this one, in infectious diseases."
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics,
commented: "It is exciting to announce that our portfolio of
adjuvants can be combined to create adjuvant systems that deliver
optimised immunotherapy in both allergy indications and infectious
disease applications. Our strategy for growth with Bencard Adjuvant
Systems focuses on extending the use of MCT with novel adjuvants to
create novel adjuvant systems capable of increasing the
effectiveness of new and existing vaccines with unmet needs, and or
new and emerging infectious diseases that require an effective
adjuvant system like AdSys-VcT."
References
(1) Mullard, A. NIAID amps up vaccine adjuvant work. Nature
Reviews Drug Discovery. 2014. 13:803.
ENDS
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura
Thornton
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
About Bencard Adjuvant Systems
Bencard Adjuvant Systems (BAS) is a division of Allergy
Therapeutics UK. Located in UK, BAS specialises in developing and
optimising adjuvants for vaccines against infectious diseases and
allergen immunotherapy. The team at BAS are committed to engaging
in long-term partnerships with those who require BAS's patented
platform of adjuvant technologies to enable successful vaccine or
immunotherapy development. For more information, please contact
www.bencard-as.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFKLLBQBFFFBL
(END) Dow Jones Newswires
October 10, 2016 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024